COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people [...]
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
01/10/2026
Professional microneedling and nano-needling device launches in UK, Ireland, Germany, France, Spain and Portugal LONG BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems (Nasdaq: SKIN), home to flagship [...]
Le SkinStylus® SteriLock MicroSystem de SkinHealth Systems désormais disponible sur le marché européen
01/10/2026
Le dispositif professionnel de microneedling et de nanoneedling fait son entrée au Royaume-Uni, en Irlande, en Allemagne, en France, en Espagne et au Portugal LONG BEACH, Californie, 01 oct. 2026 (GLOBE NEWSWIRE) -- [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG ( [...]
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
01/10/2026
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD Phase 1 study is evaluating the safety, tolerability and [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients [...]
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
01/10/2026
New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals 1-3 Advanced AI-enabled analysis of imaging [...]
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
01/10/2026
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical [...]
IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
01/10/2026
IBA to offer QUANTM ® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics Louvain-la-Neuve, Belgium – October 1st, 2026, 7 a.m. – IBA (Ion [...]
IBA et Telix renforcent leur collaboration avec un accord de distribution de la technologie QIS® d’ARTMS
01/10/2026
IBA proposera le système d’irradiation QUANTM ® aux utilisateurs de cyclotrons partout dans le monde, afin d’accélérer la production locale de radio-métaux destinés à la théranostique. Louvain-la-Neuve, Belgique, 01 [...]
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
01/10/2026
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, versus standard endocrine therapy plus everolimus 1 By targeting [...]
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
01/10/2026
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is [...]
Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
01/10/2026
Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée REGN20423, un anticorps monoclonal anti-IL-13 à action prolongée en phase clinique [...]
National MS Society Launches Campaign to End MS, Declaring for the First Time: Ending MS Is Within Reach
01/10/2026
Five-year, $1 billion campaign to lead the way in ending MS, anchored by the Society's first-ever national research symposium and a landmark day of action in New York City NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The [...]
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30/09/2026
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option [...]
Oculis Announces Resignation of Lionel Carnot from Board of Directors
30/09/2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company [...]
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
30/09/2026
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a clinical stage biotechnology company focused on developing highly selective [...]
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
30/09/2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a [...]

Pages